Q3 FY2026
Filed Nov 16, 2026Flyte Aviation reports record Q3 2026 revenue of $1,838,000, up 145% sequentially, with flight hours up 129% sequentially and a $15.1 million net loss that includes a $13.3 million MedTech impairment
The filing shows record quarterly revenue and a large sequential rise in flight activity, but it also reports a $15.1 million net loss, a $13.3 million non-cash impairment, $2.4 million of cash and cash equivalents, and no printed prior-year or prior-quarter absolute figures for the aviation business.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Record quarterly revenue (quarter ended Sept 30, 2026)other | $1,838,000 | 145% sequential increase | – |
| Time flown per leg (Q3 2026)other | 52 minutes | – | – |
| MedTech revenue (discontinued operations, Q3 2026)other | $280,000 | 4% sequential increase | 24% year-over-year |
| Net loss (Q3 2026)other | $15.1M | – | – |
| Non-cash impairment charge related to MedTech assets held for sale (Q3 2026)other | $13.3M | – | – |
| Loss from continuing operations (Q3 2026)other | $1.9M | – | – |
| Cash and cash equivalents (as of Sept 30, 2026)other | $2.4M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Aviation (continuing operations)The filing states that total flight hours increased 129% sequentially, which it attributes to increased demand and the addition of two aircraft to the fleet. More than 99% of customer flights were fulfilled on Flyte's own fleet rather than third-party charters. Average time flown per leg was 52 minutes in Q3. | $1,838,000 | 145% sequential increase | – |
| MedTech (Catheter Precision), discontinued operationsThe segment was classified as held for sale in September 2026 and its results as discontinued operations. A non-binding letter of intent to sell the segment was entered into on November 1, 2026. The company states the MedTech business continues to operate in the ordinary course pending any sale. | $280,000 | 4% sequential increase | 24% year-over-year |
What drove it
- Company states that total flight hours increased 129% sequentially, resulting from increased demand for its flights and the addition of two aircraft to its fleet.
- Company states that more than 99% of customer flights were fulfilled on its own fleet rather than more expensive third-party charters.
- Company regards the 52-minute average time flown per leg, combined with increased demand, as market affirmation of its short-hop private aviation strategy.
- Company states that in October it received its Foreign Air Operator Certificate and Transport License, filed and had accepted a Canadian tariff, and flew its first Canadian flights.
- Company launched a direct-to-consumer booking platform on July 2, a Partner Portal on October 20 and the Flyte Club membership program on November 5, per the filing.
- Company states that three aircraft are in the process of joining the fleet, have completed lessor pre-purchase inspections, and are expected to begin revenue flights in the December 2026 quarter.
Concerns
- The company reports a net loss of $15.1 million in Q3 2026, including a $13.3 million non-cash impairment charge on MedTech assets held for sale.
- Cash and cash equivalents were $2.4 million as of September 30, 2026.
- The MedTech letter of intent is non-binding. The filing states there can be no assurance that it will lead to a definitive agreement or be completed on the anticipated timeline or at all.
- The forward-looking statements section lists possible adjustments to the preliminary third quarter 2026 results and the risk of lost revenue and gross profit from the life sciences business.
- The filing states that new aircraft are being added alongside the hiring and qualification of additional pilots, and that the company anticipates adding more airplanes in the first half of 2027 and beyond. No funding or capacity figures for these additions are printed.
What to watch
- Whether the three aircraft expected in the December 2026 quarter begin revenue service on schedule.
- Whether the non-binding MedTech letter of intent becomes a definitive agreement, and the cash consideration and expense reductions that the company says it expects.
- The Form 10-Q for the third quarter, which the release says contains the detailed results, including prior-period comparatives and the figures not printed in this release.
- Whether cash and cash equivalents of $2.4 million are sufficient to fund fleet additions, pilot hiring and the Canadian and Caribbean expansion, a question the filing does not answer.
- Whether the company reports the Q3 2026 results as preliminary or revises them in later filings, as the forward-looking statements section allows.
Balance sheet and cash flow
- Cash and cash equivalents of $2.4 million as of September 30, 2026.
- Q3 2026 net loss of $15.1 million, which includes a $13.3 million non-cash impairment charge related to the MedTech assets held for sale.
- Loss from continuing operations of $1.9 million in Q3 2026.
- The filing does not print operating cash flow, free cash flow, total assets, total debt or total equity.
Analysis
Flyte Aviation reports record quarterly revenue of $1,838,000 for the quarter ended September 30, 2026, a 145% sequential increase. The release attributes the step-up to higher demand and to the addition of two aircraft, and reports that total flight hours rose 129% sequentially. It also states that more than 99% of customer flights were flown on the company's own fleet rather than third-party charters, and that average time flown per leg was 52 minutes. Taken together, these figures describe rapid growth in flying activity over a single quarter. The filing does not print a prior-year or prior-quarter revenue figure, so the year-over-year growth of the aviation business cannot be read from the document.
The presentation of results is affected by the classification of the MedTech segment as held for sale and as discontinued operations. MedTech revenue was $280,000 in the quarter, up 4% sequentially and 24% year-over-year. The company reports a net loss of $15.1 million, which includes a $13.3 million non-cash impairment charge related to the MedTech assets held for sale, and a loss from continuing operations of $1.9 million. The gap between the two loss figures is driven, according to the filing, by the MedTech impairment and the discontinued-operations treatment. Cash and cash equivalents were $2.4 million as of September 30, 2026. The release prints no operating cash flow, debt, total assets or equity figures, so the company's liquidity position against its fleet expansion plans cannot be assessed from this document.
On strategy, the company describes a shift to a pure-play private aviation business. It cites a non-binding letter of intent, dated November 1, 2026, to sell the MedTech assets, with completion targeted by year-end 2026. The company says the sale would reduce operating expenses and provide capital for growth, but the filing states that the letter is non-binding and subject to due diligence, a definitive agreement, approvals and consents. No cash consideration figure is printed. Operating initiatives listed in the release include a direct-to-consumer booking platform, a B2B Partner Portal, the Flyte Club membership program, Canadian operations approved in October, and Bahamas and Caribbean approval granted on September 2.
The outlook is qualitative. Three aircraft are expected to begin revenue flights in the December 2026 quarter, and additional airplanes are expected in the first half of 2027 and beyond. No numerical revenue, margin, expense or tax guidance is printed, so no comparison with prior guidance is possible. The company also states that the detailed third-quarter results are in its Form 10-Q, and the forward-looking statements section notes that the preliminary third-quarter results may be adjusted.
The figures that deserve attention are the sequential revenue and flight-hour growth, the $15.1 million net loss against the $13.3 million impairment and $1.9 million loss from continuing operations, and the $2.4 million cash balance set against planned fleet and pilot additions. The release is a headline-oriented summary: most comparative and cost figures sit in the Form 10-Q, which was not part of the text provided.
Management, verbatim
I am delighted with the rapid ramp up of Flyte’s revenue, aircraft utilization and more.
David Jenkins, Chief Executive Officer, Flyte Aviation
With the addition of Canada to the growing number of markets that we serve in North America, including the Bahamas and Caribbean, our capability to provide private aviation flights and increase the strength of our brand continues to broaden across the continent and attract increasing interest from new partners.
David Jenkins, Chief Executive Officer, Flyte Aviation
Not in the filing
stated, not guessed- Prior-year and prior-quarter absolute revenue for the aviation business (only the sequential percentage is printed).
- Whether the $1,838,000 figure excludes MedTech; the headline says Aviation Revenue, but the release does not state the basis of this figure explicitly.
- Total flight hours as an absolute figure (only the 129% sequential increase is printed).
- Gross margin, cost of revenue and any gross profit figures.
- Operating expenses by line, operating income or loss, and EBITDA.
- Interest expense, income tax, and per-share results including EPS (GAAP and non-GAAP).
- Prior-year and prior-quarter net loss and loss from continuing operations.
- Accounting basis (GAAP or non-GAAP) for the net loss, loss from continuing operations, and impairment figures, which the release does not label.
- Operating cash flow, investing cash flow and free cash flow.
- Total debt, total assets and total equity.
- Cash consideration, expected expense reductions and contingent consideration under the MedTech letter of intent, which are described as expected but not quantified.
- Fleet capital expenditure, lease commitments and funding plan for the three aircraft and future additions.
- Numerical guidance for revenue, flight hours, margins or expenses; the outlook is qualitative only.
- Prior-period outlook, so no vs_prior_guidance comparison could be made.
- Detailed quarterly results and comparatives, which the release says are in the Form 10-Q not provided here.
- Capital returns (buybacks or dividends); none are mentioned.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.